

Appendix 3- Reasons for exclusion at full text level with reasons for HIF-PHI in CKD patients not on dialysis

No.	Citation	Reason for Exclusion
1.	Akizawa, T., et al. "JTZ-951, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease not on dialysis." <i>Nephrology Dialysis Transplantation</i> 3: iii196.	Conference abstract, only abstract available
2.	Akizawa, T., et al. "JTZ-951, an oral novel HIF-PHD inhibitor, elevates hemoglobin in Japanese anemic patients with chronic kidney disease receiving maintenance hemodialysis." <i>Nephrology Dialysis Transplantation</i> 3: iii10	Conference abstract, only abstract available
3.	Akizawa, T., et al. "Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD." <i>Kidney Int Rep</i> 6(7): 1810-1828.	Wrong comparator
4.	Akizawa, T., et al. "Pos-244 a Phase 3, Multicenter, Randomized, Open-Label, Active Comparator Conversion Study of Roxadustat in Non-Dialysis-Dependent (Ndd) Patients with Anemia in Chronic Kidney Disease (Ckd)." <i>Kidney International Reports</i> 6: S103.	Conference abstract
5.	Akizawa, T., et al. (2020). "A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD." <i>Journal of the American Society of Nephrology</i> 31: 134.	Conference abstract
6.	Akizawa, T., et al. "Iron regulation by molidustat, bay 85-3934, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor in patients with chronic kidney disease." <i>Nephrology Dialysis Transplantation</i> 33: i457.	Conference abstract, only abstract available
7.	Akizawa, T., et al. (2018). "Molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, and vascular endothelial growth factor in patients with CKD." <i>Journal of the American Society of Nephrology</i> 29: 481.	Conference abstract, only abstract available
8.	Akizawa, T., et al. (2018). "Enarodustat (JTZ-951), an oral hif-ph inhibitor, maintains hemoglobin levels switching from ESAS over 30 weeks in japanese anemic patients with CKD receiving maintenance hemodialysis." <i>Journal of the American Society of Nephrology</i> 29: 171.	Conference abstract, Only abstract available
9.	Akizawa, T., et al. (2018). "Enarodustat (JTZ-951), an oral HIF-PH inhibitor, elevates and maintains hemoglobin levels over 30 weeks in japanese anemic	Conference abstract, Only abstract available

	patients with CKD not on dialysis." Journal of the American Society of Nephrology 29: 171.	
10.	Akizawa, T., et al. "A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study." Kidney Int Rep 6(7): 1840-1849.	Duplicate
11.	Akizawa, T., et al. (2018). "Phase 3, multicenter, open-label study of intermittent oral roxadustat in peritoneal dialysis CKD patients with anemia." Journal of the American Society of Nephrology 29: 99.	Duplicate, conference abstract
12.	Akizawa, T., et al. (2019). "Phase 3, multicenter, randomized, open-label, non-comparative study of intermittent oral roxadustat in ESA-naive CKD patients not on dialysis in Japan." Journal of the American Society of Nephrology 30: 822.	Duplicate, conference abstract, Only abstract available
13.	Akizawa T, I. M. O. T. Y. Y. R. M. (2020). "A phase 3, multicenter, randomized, open-label, active comparator conversion study of roxadustat in non-dialysis-dependent (NDD) patients with anemia in CKD." Journal of the American Society of Nephrology : JASN 31: 134.	Duplicate, Conference abstract
14.	Akizawa T, M. I. C. B. J. S. B. T. K. T. T. M. O. E. I. K. (2017). "Dialogue phase 2 extension studies of bay 85-3934, molidustat, a hif-ph inhibitor with daily oral treatment in anemic subjects with CKD." Journal of the American Society of Nephrology : JASN 28: B7.	Conference abstract
15.	Akizawa T, M. Y. M. A. K. R. A. M. (2018). "Enarodustat (JTZ-951), an oral HIF-PH inhibitor, elevates and maintains hemoglobin levels over 30 weeks in japanese anemic patients with CKD not on dialysis." Journal of the American Society of Nephrology : JASN 29: 171.	Duplicate, conference abstract, Only abstract available
16.	Akizawa T, M. Y. M. K. K. R. A. M. (2018). "Enarodustat (JTZ-951), an oral hif-ph inhibitor, maintains hemoglobin levels switching from ESAS over 30 weeks in japanese anemic patients with CKD receiving maintenance hemodialysis." Journal of the American Society of Nephrology : JASN 29: 171.	Duplicate, conference abstract
17.	Akizawa T, N. M. Y. T. O. N. K. S. O. T. E. Y. H. K. O. H. C. A. R. (2019). "Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial." Nephrology Dialysis Transplantation 34: a350.	Conference abstract, Only abstract available
18.	Akizawa T, O. T. R. M. U. M. (2018). "Phase 3, multicenter, open-label study of intermittent oral roxadustat in peritoneal dialysis CKD patients with anemia." Journal of the American Society of Nephrology: JASN 29: 99.	Duplicate, Conference abstract

19.	Akizawa T, O. T. Y. Y. R. M. (2019). "Phase 3, multicenter, randomized, open-label, non-comparative study of intermittent oral roxadustat in ESA-naive CKD patients not on dialysis in Japan." <i>Journal of the American Society of Nephrology: JASN</i> 30: 822.	Conference abstract, Only abstract available
20.	Allison, S. J. "Daprodustat for anaemia in CKD." <i>Nat Rev Nephrol</i> 18(1): 3.	Research highlights, Only abstract available
21.	Bailey, C. K., et al. "A 29-day safety, efficacy, and pharmacodynamic study of a hypoxia-inducible factor prolyl hydroxylase inhibitor, daprodustat, administered tiw in anemic subjects on hemodialysis (HD)." <i>Journal of the American Society of Nephrology</i> 28: 889.	Duplicate, conference abstract
22.	Barratt, J., et al. "Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A phase 3, randomised, open-label, activecontrolled study." <i>Nephrology Dialysis Transplantation</i> 35: iii101.	Conference abstract, Only abstract available
23.	Barratt J, A. B. T. A. S. M. R. M. V. U. (2020). "Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a phase 3, randomized, open-label, active-controlled study." <i>Swiss medical weekly</i> 150: 9S.	Conference abstract, Only abstract available
24.	Barratt J, A. B. T. A. S. M. R. M. V. U. M. C. (2021). "POS-247 Roxadustat for the treatment of anemia in chronic kidney disease (CKD) patients not on dialysis (NDD): a Phase 3, randomized, open-label, active-controlled study." <i>Kidney International Reports</i> 6(4): S104.	Conference abstract
25.	Besarab, A., et al. "Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients." <i>J Am Soc Nephrol</i> 27(4): 1225-1233.	Patients were randomized to different iron supplementation regimes and not HIF PHIs
26.	Besarab A, B. D. D. S. M. E. S. C. L. T. S. K. F. M. L. R. N. T. Y. K. H. P. (2012). "Evaluation of hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for hemoglobin correction and maintenance in nondialysis chronic kidney disease patients for 16 and 24 weeks." <i>Nephrology Dialysis Transplantation</i> 27: ii144.	Conference abstract, Only abstract available
27.	Bh, et al. (2021). "Effects of roxadustat in patients with dialysis-dependent CKD (DD-CKD) across all baseline (BL) hemoglobin (HB) values." <i>Journal of the American Society of Nephrology</i> 32: 181.	Conference abstract, Only abstract available
28.	Bunn, H. F. "Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease." <i>N Engl J Med</i> 385(16): e56.	Correspondence, Letter to the editor
29.	Charytan, C., et al. (2019). "Sierras: A phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance	Conference abstract, Only abstract available

	treatment of anemia in subjects with ESRD on stable dialysis." Journal of the American Society of Nephrology 30: 822.	
30.	Chertow, G. M., et al. (2021). "Vadadustat for treatment of anemia in patients with dialysis-dependent CKD receiving peritoneal dialysis." Journal of the American Society of Nephrology 32: 184.	Conference abstract, Only abstract available
31.	Coyne, D. W., et al. (2019). "Andes: A phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis." Journal of the American Society of Nephrology 30: 822-823.	Conference abstract, Only abstract available
32.	Coyne, D. W., et al. "Roxadustat for CKD-related Anemia in Non-dialysis Patients." Kidney International Reports 6: 624-635.	Duplicate
33.	Coyne, D. W., et al. (2021). "Ascend-TD: A randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients." Journal of the American Society of Nephrology 32: 191.	Duplicate, Conference abstract, Only abstract available
34.	Coyne Dw, S. A. K. L. R. D. B. C. K. D. T. L. H. C. C. J. J. R. A. K. S. G. (2021). "Ascend-TD: a randomized, double-blind, active-controlled study of daprodustat administered three times weekly in hemodialysis patients." Journal of the American Society of Nephrology : JASN 32: 191.	Conference abstract, Only abstract available
35.	Ctri (2017). "ZYAN1(drug) is used for the treatment of anemia in chronic kidney disease patients." A randomized, double-blind, placebo controlled, parallel group, Phase II multi-centric trial to assess safety, tolerability and efficacy of PHD-2 Inhibitor, ZYAN1 in the treatment of anemia in pre-dialysis chronic kidney disease patients.	Trial protocol, no results posted, publication details N/A
36.	Eckardt, K. U. (2020). "Global phase 3 clinical trials of vadadustat vs. darbepoetin alfa for treatment of anemia in patients with dialysis-dependent CKD." Journal of the American Society of Nephrology 31: 1	Conference abstract, Only abstract available
37.	Esposito, C., et al. (2019). "Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis." Journal of the American Society of Nephrology 30: 822.	Conference abstract, Only abstract available
38.	Euctr, A. T. (2016). "Study in subjects with anemia of chronic kidney disease to assess safety and efficacy of daprodustat compared to darbepoetin alfa."	Results published elsewhere, publication included already
39.	Euctr, D. E. (2012). "Study of a new drug's effect on anemia in subjects with impaired kidney function who are not on dialysis."	Results published elsewhere, publication included already
40.	Euctr, E. E. (2013). "A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of	Results published elsewhere, publication included already

	the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-dialysis Patients." <a href="https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-002753-30-EE">https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-002753-30-EE</a> .	
41.	Euctr, E. S. (2016). "A study to test three times weekly dosing of GSK1278863 in the treatment of anemia associated with chronic kidney disease in hemodialysis patients."	Results published elsewhere, publication included already
42.	Euctr, E. S. (2017). "Anemia Studies in CKD: erythropoiesis via a Novel PHI Daprodustat- in Incident Dialysis."	Results published elsewhere, publication included already
43.	Euctr, H. U. (2014). "Study of a new drug's effect on anemia in subjects with impaired kidney function who are undergoing hemodialysis."	Results published elsewhere, publication included already
44.	Euctr, H. U. (2016). "Efficacy and safety study to evaluate vadadustat for the correction of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD)."	Results published elsewhere, publication included already
45.	Euctr, I. T. (2013). "FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients."	Results published elsewhere, publication included already
46.	Euctr, I. T. (2020). "A study to evaluate the effectiveness and safety of a study drug called vadadustat which may be used in the maintenance treatment of anemia for hemodialysis participants, after they've converted from ESA therapy."	No results posted, trial in progress
47.	Euctr, P. T. (2016). "Efficacy and safety study to evaluate vadadustat for the maintenance treatment of anemia in subjects with dialysis-dependent chronic kidney disease (DD-CKD)."	Results published elsewhere, publication included already
48.	Euctr, S. K. (2016). "Efficacy and safety study to evaluate vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD)."	Results published in trial registry
49.	Fishbane, S., et al. (2020). "Hemoglobin (HB) correction with roxadustat is associated with improved iron homeostasis in patients with non-dialysis-dependent CKD (NDD-CKD)." <i>Journal of the American Society of Nephrology</i> 31: 130.	Conference abstract, Only abstract available
50.	Fishbane, S., et al. (2019). "Olympus: A phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia." <i>Journal of the American Society of Nephrology</i> 30: 6.	Conference abstract, Only abstract available
51.	Fishbane, S., et al. (2019). "Rockies: An international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients." <i>Journal of the American Society of Nephrology</i> 30: 6.	Conference abstract
52.	Fujii, T., et al. (2018). "Efficacy and safety of daprodustat on anemia management in Japanese	Conference abstract

	hemodialysis patients not using erythropoiesis-stimulating agents." Journal of the American Society of Nephrology 29: 171.	
53.	Haase, V. H., et al. "Vadadustat maintains stable hemoglobin levels in dialysis patients converting from erythropoiesis-stimulating agent (ESA)." American Journal of Kidney Diseases 67: A51.	Conference abstract
54.	Hartman, C. S., et al. "Controlled hemoglobin response in a double-blind, placebo-controlled trial of AKB-6548 in subjects with chronic kidney disease." Nephrology Dialysis Transplantation 3: iii22.	Conference abstract
55.	Johansen, K. L., et al. (2021). "Effects of daprodustat on hemoglobin and quality of life in patients with CKD: Results of the ascend-NHQ randomized, double-blind, placebo-controlled trial." Journal of the American Society of Nephrology 32: 36.	Conference abstract
56.	Macdougall, I. C., et al. "Molidustat increases haemoglobin in erythropoiesis stimulating agents (ESA)-naive anaemic patients with chronic kidney disease not on dialysis (CKD-ND)." Nephrology Dialysis Transplantation 1: i16.	Conference abstract
57.	Macdougall, I. C., et al. "Safety and efficacy of molidustat in erythropoiesis stimulating agents (ESA) pre-treated anaemic patients with chronic kidney disease not on dialysis (CKD-ND)." Nephrology Dialysis Transplantation 1: i193.	Conference abstract
58.	Nangaku, M., et al. (2018). "Randomized, placebo-controlled phase 2 trials of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), to treat anemia of ckd." Journal of the American Society of Nephrology 29: 171.	Conference abstract
59.	Nangaku, M., et al. (2019). "Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan." Journal of the American Society of Nephrology 30: 823.	Conference abstract
60.	Nangaku, M., et al. "Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan." Ther Apher Dial 25(5): 642-653.	Not an Randomized Controlled Trial (RCT)
61.	Nangaku, M., et al. (2019). "Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan." Journal of the American Society of Nephrology 30: 6.	Conference abstract
62.	Nct (2012). "4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis."	Published trial, publication included already
63.	Nct (2012). "A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis."	Published trial

<b>64.</b>	Nct (2012). "4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease."	Published trial, publication included already
<b>65.</b>	Nct (2013). "A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)."	Published trial
<b>66.</b>	Nct (2013). "ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis."	Published trial,publication details N/A
<b>67.</b>	Nct (2014). "Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis."	Published trial
<b>68.</b>	Nct (2014). "Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis."	Published trial, publication included already
<b>69.</b>	Nct (2014). "Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects."	Published trial
<b>70.</b>	Nct (2016). "FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease."	Published trial, publication included already
<b>71.</b>	Nct (2016). "FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis."	Ongoing trial, Publication included already
<b>72.</b>	Nct (2016). "Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)."	Published trial, Publication included already
<b>73.</b>	Nct (2016). "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)."	Ongoing trial, publication included already
<b>74.</b>	Nct (2016). "Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)."	Published trial, publication included already
<b>75.</b>	Nct (2016). "Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)."	Published trial
<b>76.</b>	Nct (2016). "Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia."	Published trial, publication included already
<b>77.</b>	Nct (2017). "Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)."	Published trial
<b>78.</b>	Nct (2017). "Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to	Published trial

	Dialysis-Dependent Chronic Kidney Disease (DD-CKD)."	
79.	Nct (2017). "Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents."	Publication details N/A
80.	Nct (2018). "Anemia Studies in Chronic Kidney Disease (CKD): erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)."	Ongoing trial
81.	Nct (2018). "Anemia Studies in Chronic Kidney Disease (CKD): erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)."	Published trial
82.	Nct (2019). "Desidustat in the Treatment of Anemia in CKD."	Ongoing trial, publication details N/A
83.	Nct (2019). "Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Subjects With Chronic Kidney Disease."	Ongoing trial, publication details N/A
84.	Nct (2019). "Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients."	Published trial, full text not available
85.	Nct (2019). "Study of Vadadustat in Hemodialysis Patients With Anemia Switching From Epoetin Alfa."	Ongoing trial, Publication details N/A
86.	Nct (2020). "A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)."	Ongoing trial, publication details N/A
87.	Nct (2020). "Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)."	Ongoing trial, trial in progress
88.	Nct (2020). "Desidustat in the Treatment of Anemia in CKD on Dialysis Patients."	Ongoing trial, publication details N/A
89.	Nct (2021). "Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting."	Ongoing trial, trial in progress
90.	Nct (2021). "HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia."	Ongoing trial, trial in progress
91.	Neumann, M. E. (2020). "HIMALAYAS trial: Roxadustat superior to epoetin alfa in raising hemoglobin levels." Nephrology News & Issues 34(1): 15-15.	Editorial, full text not available
92.	Parfrey, P. S., et al. (2021). "Thromboembolic events with vadadustat vs. darbepoetin alfa for anemia	Conference abstract



	treatment in patients with dialysis-dependent CKD." Journal of the American Society of Nephrology 32: 184.	
<b>93.</b>	Parmar, D. and K. Kansagra "Mon-318 a Phase II Trial to Assess Safety, Tolerability and Efficacy of Phd-2 Inhibitor (Desidustat-Zyan1) in the Treatment of Anemia in Pre-Dialysis Chronic Kidney Disease Patients." Kidney International Reports 4: S430.	Conference abstract
<b>94.</b>	Per (2015). "A phase 3, Multicentre, randomized, open-label, active controlled study of the safety and efficacy of roxadustat in the treatment of anemia in dialysis patients." <a href="https://trialssearch.who.int/Trial2.aspx?TrialID=PER-067-14">https://trialssearch.who.int/Trial2.aspx?TrialID=PER-067-14</a> .	Ongoing trial, publication details N/A
<b>95.</b>	Per (2015). "A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis." <a href="https://trialssearch.who.int/Trial2.aspx?TrialID=PER-068-14">https://trialssearch.who.int/Trial2.aspx?TrialID=PER-068-14</a> .	Ongoing trial, publication details N/A
<b>96.</b>	Pergola, P., et al. "Pos-283 Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Non-Dialysis-Dependent (NDD) and Dialysis-Dependent (DD) Chronic Kidney Disease (CKD)." Kidney International Reports 6: S120-S121.	Conference abstract
<b>97.</b>	Pergola, P. E., et al. (2020). "Hemoglobin (HB) correction with roxadustat is associated with improved iron homeostasis in patients with dialysis-dependent CKD (DD-CKD)." Journal of the American Society of Nephrology 31: 2.	Conference abstract
<b>98.</b>	Pergola, P. E., et al. "AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) for the treatment of anemia in patients with chronic kidney disease not on dialysis (ND-CKD)." Nephrology Dialysis Transplantation 3: iii8.	Conference abstract
<b>99.</b>	Provenzano, R., et al. (2019). "Himalayas: A phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients." Journal of the American Society of Nephrology 30: 5.	Duplicate, Conference abstract
<b>100.</b>	Provenzano, R., et al. "Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor FG-2216 increases Hb without FE depletion in the absence of IV Fe." American Journal of Kidney Diseases 61: A78.	Conference abstract
<b>101.</b>	Provenzano, R., et al. "Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and	Wrong outcome

	Pharmacodynamic Profiles in Hemodialysis Patients." <i>Journal of Clinical Pharmacology</i> 60: 1432-1440.	
102.	Provenzano R, E. S. L. E. K. S. K. A. A. P. L. S. G. B. C. E. M. B. A. L. R. L. C. (2019). "Himalayas: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients." <i>Journal of the American Society of Nephrology : JASN</i> 30: 5.	Conference abstract
103.	Rastogi, A., et al. (2020). "Roxadustat treatment corrects anemia to hemoglobin (HB) values $\geq 10$ g/dl in the majority of patients with non-dialysis-dependent chronic kidney disease (NDD-CKD)." <i>Journal of the American Society of Nephrology</i> 31: 133.	Conference abstract
104.	Singh, A. K. (2021). "Daprodustat is noninferior to darbepoetin alfa in treating anemia in incident dialysis patients." <i>Journal of the American Society of Nephrology</i> 32: 184-185.	Conference abstract
105.	Slctr (2019). "A Randomized, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Desidustat Versus Darbepoetin for the Treatment of Anemia in Patients with Chronic Kidney Disease (CKD) who are not on Dialysis."	Ongoing trial
106.	Tsubakihara, Y., et al. "A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients." <i>Ther Apher Dial</i> 24(2): 108-114.	Not an Randomized Control Trial (RCT)
107.	Yamamoto, H., et al. "Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies." <i>BMJ Open</i> 9(6): e026704.	Study protocol, No result provided, just explained design of trial
108.	Yamamoto, H., et al. "To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are treated with erythropoiesis stimulating agents: Miyabi ND-M." <i>Nephrology Dialysis Transplantation</i> 35: iii2179.	Conference abstract
109.	Yamamoto, H., et al. "To investigate the efficacy and safety of molidustat in non-dialysis patients with renal anemia who are not treated with erythropoiesis stimulating agents: miyabi nd-c." <i>Nephrology Dialysis Transplantation</i> 35: iii2177.	Conference abstract
110.	Akizawa T, Nangaku M, Yamaguchi T, et al. Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. <i>Nephron</i> . 2019;143(2):77-85.	Wrong population- Patients were on dialysis Wrong comparator of interest- Placebo
111.	Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. <i>Am J Nephrol</i> . 2017;45(2):127-135.	Wrong population- Patients were on dialysis Wrong comparator of interest- Placebo

112.	Bailey CK, Caltabiano S, Cobitz AR, Huang C, Mahar KM, Patel VV. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. <i>BMC Nephrol.</i> Oct-16 2019;20(1):372.	Wrong population- Patients were on dialysis Wrong comparator of interest- Placebo
113.	Brigandi RA, Johnson B, Oei C, et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. <i>Am J Kidney Dis.</i> Jun 2016;67(6):861-71.	Wrong population- Patients were on dialysis Wrong comparator of interest- Placebo
114.	Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. <i>Clin Kidney J.</i> Feb 2019;12(1):139-148.	Wrong population- Patients were on dialysis Wrong comparator of interest- Placebo
115.	Nangaku M, Farag YMK, deGoma E, Luo W, Vargo D, Khawaja Z. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. <i>Nephrol Dial Transplant.</i> Jul-28 2021;	Wrong population- Patients were on dialysis Wrong comparator of interest- Placebo
116.	Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. <i>Ther Apher Dial.</i> Apr 2020;24(2):115-125.	Wrong population- Patients were on dialysis No comparator arm
117.	Yang Z, Ma T, Xu X, et al. Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis. <i>Kidney Int Rep.</i> Mar 7(3):455-464.	Wrong population- Patients were on dialysis No comparator arm
118.	Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. <i>J Am Soc Nephrol.</i> Jul 2020;31(7):1628-1639.	Wrong population- Patients were on dialysis
119.	Akizawa T, Nangaku M, Yamaguchi T, et al. A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. <i>Kidney Dis (Basel).</i> Nov 2021;7(6):494-502.	Wrong population- Patients were on dialysis
120.	Akizawa T, Yamada T, Nobori K, et al. Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis. <i>Kidney Int Rep.</i> Oct 2021;6(10):2604-2616.	Wrong population- Patients were on dialysis

<b>121.</b>	Akizawa T NM, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR. . Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. <i>Clin J Am Soc Nephrol</i> . 2020;15(8):1155-1165. doi:10.2215/CJN.16011219	Wrong population- Patients were on dialysis
<b>122.</b>	Charytan C, Manllo-Karim R, Martin ER, et al. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. <i>Kidney International Reports</i> . July 2021;6:1829-1839.	Wrong population- Patients were on dialysis
<b>123.</b>	Chen N, Hao C, Liu BC, et al. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis. <i>N Engl J Med</i> . Sep-12 2019;381(11):1011-1022.	Wrong population- Patients were on dialysis
<b>124.</b>	Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. <i>Nephrol Dial Transplant</i> . Aug-1 2017;32(8):1373-1386.	Wrong population- Patients were on dialysis
<b>125.</b>	Coyne DW SA, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. . Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. . <i>Clin J Am Soc Nephrol</i> . 2018 2022;17(9):1325–36. doi:10.2215/CJN.00550122.	Wrong population- Patients were on dialysis
<b>126.</b>	Csiky B, Schömig M, Esposito C, et al. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES). <i>Adv Ther</i> . Oct 2021;38(10):5361-5380.	Wrong population- Patients were on dialysis
<b>127.</b>	Eckardt KU, Agarwal R, Aswad A, et al. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. <i>N Engl J Med</i> . Apr-29 2021;384(17):1601-1612.	Wrong population- Patients were on dialysis
<b>128.</b>	Fishbane S, Pollock CA, El-Shahawy M, et al. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study. <i>J Am Soc Nephrol</i> . Apr 2022;33(4):850-866.	Wrong population- Patients were on dialysis
<b>129.</b>	Gang S KP, Varade D, Chinta VR, Mavani S, Gupta U, Reddy SVK, Rajanna S, Jeloka T, Ruhela V, Kansagra K, Kanani P, Bhatt J, Zala K Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase	Wrong population- Patients were on dialysis

	3 Study (DREAM-D). <i>Am J Nephrol.</i> 2022;53(5):343-351.	
130.	Holdstock L, Meadowcroft AM, Maier R, et al. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. <i>J Am Soc Nephrol.</i> Apr 2016;27(4):1234-44.	Wrong population- Patients were on dialysis
131.	Hou Y-P, Mao X-Y, Wang C, et al. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial. <i>Journal of the Formosan Medical Association.</i> 2022 2022;121(2):529-538.	Wrong population- Patients were on dialysis
132.	Macdougall IC AT, Berns JS, Bernhardt T, Krueger T Effects of Molidustat in the Treatment of Anemia in CKD. <i>Clin J Am Soc Nephrol.</i> 2019;14(1):28-39. doi:10.2215/CJN.02510218	Wrong population- Patients were on dialysis
133.	Nangaku M, Kondo K, Ueta K, et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. <i>Nephrol Dial Transplant.</i> Aug-27 2021;36(9):1731-1741.	Wrong population- Patients were on dialysis
134.	Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. <i>Am J Kidney Dis.</i> Jun 2016;67(6):912-24.	Wrong population- Patients were on dialysis
135.	Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. <i>Nephrology Dialysis Transplantation.</i> 01-Sep 2021;36:1717-1730.	Wrong population- Patients were on dialysis
136.	Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. <i>N Engl J Med.</i> Dec-16 2021;385(25):2325-2335.	Wrong population- Patients were on dialysis
137.	Singh AK, Cizman B, Carroll K, et al. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. <i>JAMA Intern Med.</i> Apr-4 2022;	Wrong population- Patients were on dialysis
138.	Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. <i>Nephrol Dial Transplant.</i> Oct 2015;30(10):1665-73.	Wrong comparator of interest- Placebo

139.	Brigandi RA, Johnson B, Oei C, et al. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial. <i>Am J Kidney Dis</i> . Jun 2016;67(6):861-71.	Wrong comparator of interest-Placebo
140.	Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. <i>New England Journal of Medicine</i> . 12-Sep 2019;381:1001-1010.	Wrong comparator of interest-Placebo
141.	Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. <i>Nephrol Dial Transplant</i> . Aug-1 2017;32(8):1373-1386.	Wrong comparator of interest-Placebo
142.	Coyne Dw RSDSSKSGCAAMMACTMBACW. Roxadustat for CKD-related Anemia in Non-dialysis Patients. <i>Kidney international reports</i> . 2021 2021;6(3):624.	Wrong comparator of interest-Placebo
143.	Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. <i>J Am Soc Nephrol</i> . Mar 2021;32(3):737-755.	Wrong comparator of interest-Placebo
144.	Holdstock L, Meadowcroft AM, Maier R, et al. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. <i>J Am Soc Nephrol</i> . Apr 2016;27(4):1234-44.	Wrong comparator of interest-Placebo
145.	Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. <i>Am J Nephrol</i> . 2017 2017;45(5):380-388.	Wrong comparator of interest-Placebo
146.	Nangaku M, Farag YMK, deGoma E, Luo W, Vargo D, Khawaja Z. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. <i>Nephrol Dial Transplant</i> . Jul-28 2021;	Wrong comparator of interest-Placebo
147.	Parmar DV, Kansagra KA, Patel JC, et al. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study. <i>Am J Nephrol</i> . 2019;49(6):470-478.	Wrong comparator of interest-Placebo
148.	Akizawa, T, Yusuke Y, Tetsuro O, Michael R. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis. <i>Nephron</i> . 2020;144(8): 372-382.	Wrong comparator of interest-HIF-PHI (Roxadustat)